P1vital® PReDicT Test
A Breakthrough Device to Manage the Treatment of Depression
Currently it takes 4–6 weeks after starting antidepressant therapy before a physician can detect whether the treatment is working, and more than 50% of patients fail to respond to the first antidepressant prescribed. Therefore, it can take months before a physician identifies an effective antidepressant therapy for their patient. During this time a patient’s ability to work and function socially is severely impaired. Consequently, patients with depression may be absent from work for many months and this places a substantial burden on the individual, their family, healthcare resources and the economy. Our CE marked* P1vital® PReDicT Test is the first device of its kind, and can predict whether or not an antidepressant is working within 1 week of starting treatment.
So how does the P1vital® PReDicT Test work?
Patients complete a simple computerised test online both before and after one week of antidepressant treatment. The P1vital® PReDicT Test device measures subtle changes in the way patients interpret emotional information which is a predictor of subsequent mood change 4-6 weeks later. The P1vital® PReDicT Test can be completed by patients within a clinical facility or at home, with results and associated information presented in a simple-to-understand view. Find out more about:
The PReDicT Project
The objective of the PReDicT project (Predicting Response to Depression Treatment) is to conduct clinical, health economic and commercial research to validate the clinical performance and to complete the pre-commercial development of the P1vital® PReDicT Test. On completion of the PReDicT Project, the P1vital® PReDicT Test will be ready for market launch.
*The P1vital® PReDicT Test has been registered as a CE marked Class I medical device under the Medical Devices Directive (MDD) 93/42/EEC as amended
The future of PReDicT
Starting in 2018 product design of the commercial i-spero® system was initiated, powered by the P1vital® PReDicT Test. We were awarded Innovate UK Test Bed programme to test i-spero® for the NHS depression treatment pathway in Kent and Coastal and Canterbury CCGs.